Gemtesa, an oral medication for overactive bladder (OOB) with urgency, urinary incontinence, and urinary urgency, is approved with specific labeling requirements. The drug functions as a beta-3 adrenergic agonist, relaxing the detrusor smooth muscle to increase bladder capacity.
What is the approved indication for Gemtesa?
Gemtesa (vibegron) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of urinary urgency, urinary incontinence, and urinary urgency-frequency in adult women with overactive bladder (OOB) [1].
How does Gemtesa work?
Gemtesa is a selective beta-3 adrenergic agonist. By activating beta-3 adrenergic receptors in the detrusor smooth muscle of the bladder, it causes relaxation of this muscle. This relaxation leads to an increase in bladder capacity [1].
Are there any specific warnings or precautions for Gemtesa?
The FDA label for Gemtesa includes warnings and precautions. It is important for healthcare providers to consider the drug's potential impact on blood pressure, as beta-3 adrenergic agonists can increase blood pressure. Patients with existing uncontrolled hypertension should be monitored. Additionally, Gemtesa has not been extensively studied in patients with severe renal impairment or moderate to severe hepatic impairment, and its use in these populations requires caution [1].
What are the common side effects of Gemtesa?
Common side effects reported in clinical trials for Gemtesa include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection. The incidence of these side effects is generally comparable to placebo in clinical studies [1].
How is Gemtesa taken?
Gemtesa is administered orally once a day at a recommended dose of 75 mg. It can be taken with or without food. Patients should be advised to swallow the tablet whole and not to chew, divide, or crush it [1].
When does the patent for Gemtesa expire?
Information regarding the patent expiry for Gemtesa can be found on DrugPatentWatch.com. Patent information is crucial for understanding when generic versions of a drug may become available [2].